Increased advanced glycation end-products (AGEs) assessed by skin autofluorescence in schizophrenia

Journal of Psychiatric Research

Volumn 47, Issue 8, 2013, Pages 1044-1048

  Kouidrat, Youssef ^a   Amad, Ali ^b,c   Desailloud, Rachel ^a   Diouf, Momar ^a   Fertout, Eva ^a   Scoury, Daphné ^a   Lalau, Jean Daniel ^a   Loas, Gwenolé ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIV LILLE   (France)

Author keywords

Advanced glycation end products (AGEs); Cardiovascular disease; Kraepelinian schizophrenia; Oxidative stress; Schizophrenia

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE; HEMOGLOBIN A1C; OLANZAPINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUTOFLUORESCENCE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; KRAEPELINIAN SCHIZOPHRENIA; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; METABOLIC SYNDROME X; OXIDATIVE STRESS; PILOT STUDY; PRIORITY JOURNAL; SCHIZOPHRENIA; SKIN AUTOFLUORESCENCE; SMOKING;

EID: 84878628616     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.03.016     Document Type: Article

References (31)

1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2009, 33:S62-S69.
2. Arai M., Yuzawa H., Nohara I., Ohnishi T., Obata N., Iwayama Y., et al. Enhanced carbonyl stress in a subpopulation of schizophrenia. Archives of General Psychiatry 2010, 67:589-597.
3. Basta G., Lazzerini G., Massaro M., Simoncini T., Tanganelli P., Fu C., et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002, 105:816-822.
4. Bernal-Mizrachi C., Gates A.C., Weng S., Imamura T., Knutsen R.H., DeSantis P., et al. Vascular respiratory uncoupling increases blood pressure and atherosclerosis. Nature 2005, 435:502-506.
5. Bitanihirwe B.K.Y., Woo T.-U.W. Oxidative stress in schizophrenia: an integrated approach. Neuroscience & Biobehavioral Reviews 2011, 35:878-893.
6. Cerami C., Founds H., Nicholl I., Mitsuhashi T., Giordano D., Vanpatten S., et al. Tobacco smoke is a source of toxic reactive glycation products. Proceedings of the National Academy of Sciences of United States of America 1997, 94:13915-13920.
7. De Hert M., Correll C.U., Bobes J., Cetkovich-Bakmas M., Cohen D., Asai I., et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011, 10:52-77.
8. DiMauro S., Schon E.A. Mitochondrial disorders in the nervous system. Annual Review of Neuroscience 2008, 31:91-123.
9. Emanuele E., Martinelli V., Carlin M.V., Fugazza E., Barale F., Politi P. Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with different psychiatric disorders. Neuroscience Letters 2011, 487:99-102.
10. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. American Journal of Psychiatry 2010, 167:686-693.
11. Gerrits E.G., Lutgers H.L., Kleefstra N., Graaff R., Groenier K.H., Smit A.J., et al. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008, 31:517-521.
12. Hyogo H., Yamagishi S., Iwamoto K., Arihiro K., Takeuchi M., Sato T., et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 2007, 22:1112-1119.
13. Keefe R.S., Mohs R.C., Losonczy M.F., Davidson M., Silverman J.M., Kendler K.S., et al. Characteristics of very poor outcome schizophrenia. American Journal of Psychiatry 1987, 144:889-895.
14. Loas G., Descle P., Yon V. Mortality in Kraepelinian schizophrenic patients: a prospective study with a median follow-up of 8.4 years. Comprehensive Psychiatry 2010, 51:151-156.
15. Lowell B.B., Shulman G.I. Mitochondrial dysfunction and type 2 diabetes. Science 2005, 307:384-387.
16. Lutgers H.L., Gerrits E.G., Graaff R., Links T.P., Sluiter W.J., Gans R.O., et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009, 52:789-797.
17. Meerwaldt R., Graaff R., Oomen P.H.N., Links T.P., Jager J.J., Alderson N.L., et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004, 47:1324-1330.
18. Meerwaldt R., Hartog J.W.L., Graaff R., Huisman R.J., Links T.P., Den Hollander N.C., et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. Journal of the American Society of Nephrology 2005, 16:3687-3693.
19. Meerwaldt R., Lutgers H.L., Links T.P., Graaff R., Baynes J.W., Gans R.O.B., et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007, 30:107-112.
20. Miyata T., Wada Y., Cai Z., Iida Y., Horie K., Yasuda Y., et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney International 1997, 51:1170-1181.
21. Mulder D.J., Van Haelst P.L., Gross S., De Leeuw K., Bijzet J., Graaff R., et al. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 2008, 197:217-223.
22. NCEP Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Journal of the American Medical Association 2001, 285:2486-2497.
23. Noordzij M.J., Lefrandt J.D., Graaff R., Smit A.J. Dermal factors influencing measurement of skin autofluorescence. Diabetes Technology & Therapeutics 2011, 13:165-170.
24. Osborn D.P.J., Levy G., Nazareth I., Petersen I., Islam A., King M.B. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Archives of General Psychiatry 2007, 64:242-249.
25. Saha S., Chant D., McGrath J. Asystematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Archives of General Psychiatry 2007, 64:1123-1131.
26. Sartorius N., Kaelber C.T., Cooper J.E., Roper M.T., Rae D.S., Gulbinat W., et al. Progress toward achieving a common language in psychiatry. Results from the field trial of the clinical guidelines accompanying the WHO classification of mental and behavioral disorders in ICD-10. Archives of General Psychiatry 1993, 50:115-124.
27. Smit A.J., Lutgers H.L. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Current Medicinal Chemistry 2004, 11:2767-2784.
28. Stitt A.W., He C., Friedman S., Scher L., Rossi P., Ong L., et al. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Molecular Medicine 1997, 3:617-627.
29. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet 1994, 344:793-795.
30. Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Experimental Gerontology 2011, 46:217-224.
31. Yan S.F., Ramasamy R., Naka Y., Schmidt A.M. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circulation Research 2003, 93:1159-1169.